Phase Ia/Ib Open Label, Multi-Centre Dose Escalation Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of DSB2455 as Monotherapy or in Combination With Anti-Cancer Agents in Participants With Advanced Malignancies
Latest Information Update: 17 May 2025
At a glance
- Drugs DSB 2455 (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Duke Street Bio
Most Recent Events
- 30 Oct 2024 Status changed from not yet recruiting to recruiting.
- 19 Jun 2024 New trial record